TRADING UPDATES: Ecofin US Renewables expects to pay reduced dividend
29th Jun 2023 18:55
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Polarean Imaging PLC shares were down on Friday despite slimming its annual loss, as the company said it now will focus on gaining commercial traction and exploring further financing for its newly US Food & Drug Administration-approved Xenoview device. Read More
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately "to pursue new challenges". Clark will "support [Destiny] for a limited period to ensure an orderly handover." Non-Executive Director Debra Barker will serve as interim CEO until Destiny appoints a permanent replacement. Barker has held "key roles" at Novartis AG and Polyphor AG, now named Spexis AG. She also has previously worked at Roche Holding AG, Polyneuron Pharmaceuticals AG and GSK PLC. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Pretax loss widens to GBP7.7 million for 2022 from GBP6.3 million in 2021. Administrative expenses increase to GBP7.4 million from GBP6.0 million a year earlier. Research & development expenditure amounts to GBP4.9 million, up from GBP3.7 million in 2021. Looking ahead, Destiny Pharma says it will focus on completing the manufacturing scale-up to deliver clinical trial material for the NTCD-M3 clinical programme being run by our partner Sebela. Chief Executive Officer Neil Clark says: "Destiny Pharma has made good progress in 2022 and in the first quarter of 2023." Read More
Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology - Gets 33% take-up of open offer of shares, raising GBP340,000. Destiny raises GBP7.3 million gross in total from the open offer, plus a share placing and subscription, all at 35 pence per share. Net proceeds are GBP6.7 million, which will be used to support a collaboration agreement in the US with Sebela Pharmaceuticals for NTCD-M3, Destiny's lead asset for the prevention of clostridioides difficile infection recurrence. Read More
(Alliance News) - Destiny Pharma PLC on Friday said that it has signed a collaboration agreement with Sebela Pharmaceuticals for NTCD-M3, its lead asset for the prevention of clostridioides difficile infection recurrence. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant. Read More
(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation. Read More
(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections. Read More
(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug. Read More
(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets. Read More
(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA. Read More